Versartis
Develop, manufacture and commercialize novel therapeutics to improve and transform treatment for patients with orphan endocrine disorders.
Launch date
Employees
Market cap
-
Enterprise valuation
€200—300m (Dealroom.co estimates Feb 2014.)
Menlo Park California (HQ)
Financials
Estimates*
EUR | 2015 | 2016 | 2017 |
---|---|---|---|
R&D budget | 55.0m | 68.0m | 79.0m |
Source: Dealroom estimates
Date | Investors | Amount | Round |
---|---|---|---|
- | N/A | - | |
$11.0m | Series A | ||
$21.0m | Series B | ||
N/A | $25.0m | Series C | |
N/A | $12.5m | Series C | |
$20.0m | Series D | ||
$55.0m | Series E | ||
* | N/A | Merger | |
Total Funding | €131m |
Related Content
Recent News about Versartis
EditTech stack
Tech stackLearn more about the technologies and tools that this company uses.